Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrated Biomarker and Imaging Study – 2 (IBIS-2)
2005-001556-20Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of darapladib in atherosclerosis, coronary arteriosclerosis and cardiac morbidity, sponsored by GSK. Primary endpoints: Plasma hsCRP levels after 52 weeks of SB-480848 treatment and Density of high strain spots in non-intervened coronary artery segments by palpography. Started Sep 2005; status: completed.
02
Drugs
darapladib
03
Conditions
atherosclerosiscoronary arteriosclerosiscardiac morbidity
Beyond the preview
Go deeper on 2005-001556-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001556-20.